儿童急性肾损伤的生物标志物——我们目前处于什么阶段？
Biomarkers for acute kidney injury in children - where are we now?
作者信息
Sandokji Ibrahim, Greenberg Jason H
机构信息
Department of Pediatrics, Section of Nephrology, Taibah University College of Medicine, Medina, Saudi Arabia.
Department of Pediatrics, Section of Nephrology, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
出版信息
Curr Opin Pediatr. 2023 Apr 1;35(2):245-250. doi: 10.1097/MOP.0000000000001217. Epub 2023 Jan 5.
PURPOSE OF REVIEW
Review the literature over the last 2 years on commonly evaluated biomarkers of acute kidney injury (AKI) and highlight the findings of these biomarkers.
RECENT FINDINGS
Among several studied AKI biomarkers, urine neutrophil gelatinase-associated lipocalin (NGAL) and the combination of urine tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) have been recently studied most frequently as diagnostic biomarkers of AKI and for AKI risk stratification. Urine NGAL has continued to show good discriminative value to predict and diagnose AKI in childhood. Urine TIMP-2∗IGFBP7 can provide modest improvement to clinical models of AKI.
SUMMARY
Prior research supports that AKI biomarkers may identify AKI at an earlier time point and indicate clinically meaningful tubular injury. More effort should be made to understand if AKI biomarkers can guide treatments and improve outcomes.
综述目的
回顾过去两年中关于急性肾损伤（AKI）常用评估生物标志物的文献，并突出这些生物标志物的研究结果。
最新发现
在几种研究的AKI生物标志物中，尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）以及尿金属蛋白酶组织抑制剂-2（TIMP-2）和胰岛素样生长因子结合蛋白7（IGFBP7）的组合最近作为AKI的诊断生物标志物和AKI风险分层进行了最频繁的研究。尿NGAL在预测和诊断儿童AKI方面继续显示出良好的鉴别价值。尿TIMP-2*IGFBP7可为AKI临床模型提供适度改善。
总结
先前的研究支持AKI生物标志物可能在更早的时间点识别AKI，并表明具有临床意义的肾小管损伤。应做出更多努力来了解AKI生物标志物是否能指导治疗并改善预后。
Zotero 插件